Tag: natalizumab
Natalizumab treatment may preserve upper limb function in secondary progressive MS
Results from a trial of natalizumab in secondary progressive MS suggest anti-inflammatory treatments could slow disability accumulation, even after significant function has been lost.
Alternative to natalizumab in people at risk of a brain infection
Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy
Natalizumab is more effective than fingolimod in reducing relapses
French researchers compare oral and injectable drugs for relapsing-remitting MS
Recommended treatment after stopping natalizumab
Switching from natalizumab to an alternative drug may prevent disease reactivation
Early identification of progressive multifocal leukoencephalopathy in patients on natalizumab
A method for early detection of Natalizumab-associated progressive multifocal leukoencephalopathy in the absence of clinical symptoms
Switching to second-line disease-modifying drugs
Study shows that switching to natalizumab is more effective than switching to fingolimod
Natalizumab improves walking in relapsing-remitting MS
Natalizumab is associated with clinically meaningful improvements in walking speeds
Better test for risk of PML infection in Natalizumab patients
The new test measures the risk of PML infection in people being treated with Natalizumab